Cargando…

A real‐world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)

AIM: This is a pre‐post observational study from an endocrinology ambulatory care practice which assessed the effectiveness and safety following the addition of a glucagon‐like peptide‐1 (GLP‐1) agonist, weekly exenatide (Bydureon), to basal insulin therapy in patients with type 2 diabetes mellitus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stryker, Matthew D., Kane, Michael P., Busch, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360919/ https://www.ncbi.nlm.nih.gov/pubmed/30815541 http://dx.doi.org/10.1002/edm2.4

Ejemplares similares

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2023)

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care
por: Nunes, Anthony P., et al.
Publicado: (2017)

The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial
por: Retnakaran, Ravi, et al.
Publicado: (2022)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Seewoodhary, Jason, et al.
Publicado: (2010)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018)

Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China
por: Chen, Minyuan, et al.
Publicado: (2022)

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018)

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study
por: Morgan, Christopher Ll., et al.
Publicado: (2018)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
por: Blevins, Thomas, et al.
Publicado: (2016)

Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable‐drug‐naïve elderly or renal impaired patients with type 2 diabetes in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
por: Rosenstock, J., et al.
Publicado: (2015)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders, William B, et al.
Publicado: (2016)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
por: Du, Xuan, et al.
Publicado: (2018)

First insulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia
por: TSAI, Shih-Tzer, et al.
Publicado: (2011)

Basal Insulin Dose Titration for Glycemic Control in Patients With Type 2 Diabetes Mellitus in Thailand: Results of the REWARDS Real-World Study
por: Deerochanawong, Chaicharn, et al.
Publicado: (2020)

Acute cholecystitis – a cohort study in a real-world clinical setting (REWO study, NCT02796443)
por: Blythe, Jennifer, et al.
Publicado: (2018)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
por: Tatarkiewicz, K, et al.
Publicado: (2013)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud, Aditya, et al.
Publicado: (2015)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide
por: DeKoven, Mitch, et al.
Publicado: (2014)

Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals
por: LaRue, Susan, et al.
Publicado: (2018)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
por: Gaebler, Julia A, et al.
Publicado: (2012)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j2cd68h6toig5pss82i1s5jl8p